Asset / Drug

Herceptin

Drug and asset intelligence for Herceptin with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 5
Stage: Development stage unavailable

Sponsor company

Roche →

Recent signals(3)

ClinicalJune 18, 2026

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

ClinicalJune 17, 2026

Study on Early Rehabilitation Protocol for Breast Cancer Surgery Shows Promising Safety and Feasibility

A new early rehabilitation protocol, EMOVE-BCS-LaFe, is being evaluated for safety and feasibility in breast cancer surgery patients.

ClinicalJune 17, 2026

Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines

A multi-center, retrospective study will analyze real-world data from 3,500 patients with breast phyllodes tumors in China.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(5)

Topline Data

Roche — Herceptin

Monitor results on changes in sexual function and adherence rates post-intervention.

June 18, 2026 · N/A

Topline Data

Roche — Herceptin

Monitor developments in therapies targeting lipid metabolism in HER2+ breast cancer and any clinical trials involving STARD10.

June 17, 2026 · N/A

Topline Data

— Herceptin

Monitor the study's completion and results regarding safety, adherence, and functional outcomes over the three-month follow-up period.

June 17, 2026 · N/A

Topline Data

Roche — Herceptin

Monitor the study's progress and outcomes related to local recurrence, distant metastasis, and overall survival metrics.

June 17, 2026 · N/A

Topline Data

Roche — Herceptin

Monitor trial results and any subsequent changes in treatment guidelines or market access strategies for HER2-targeted therapies.

June 17, 2026 · N/A

Indications

Breast Cancer →

Therapeutic areas

Breast Cancer →

Breast Tumors →

Oncology →

Oncology · Breast Cancer →

Oncology · Breast Tumors →

Oncology · HER2-positive Breast Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.